Abstract:To examine the relationship between opioid and HIV‐1‐induced alterations in striatal monoamine concentrations and behavior, morphine was administered to HIV‐1 Tat transgenic mice for 2 weeks or 2 months. Morphine and Tat interacted to alter levels of dopamine, dopamine metabolites, norepinephrine, and 5‐hydroxyindoleacetic acid depending on the duration of exposure and neurotransmitter/metabolite assayed. Co‐exposure to Tat and morphine disrupted locomotor activity in a time‐dependent manner. Alternatively, Tat alone inhibited social exploratory behavior, whereas morphine alone tended to increase novelty‐seeking behavior. The data suggest that Tat and morphine effects on monoamine neurochemistry are complex and contribute to motor and exploratory behavioral dysregulation. Despite the advent of combination anti‐retroviral therapy (cART), nearly half of people infected with HIV treated with cART still exhibit HIV‐associated neurocognitive disorders (HAND). HAND can be worsened by co‐morbid opioid use disorder. The basal ganglia are particularly vulnerable to HIV‐1 and exhibit higher viral loads and more severe pathology, which can be exacerbated by co‐exposure to opioids. Evidence suggests that dopaminergic neurotransmission is disrupted by HIV exposure, however, little is known about whether co‐exposure to opioids may alter neurotransmitter levels in the striatum and if this in turn influences behavior. Therefore, we assayed motor, anxiety‐like, novelty‐seeking, exploratory, and social behaviors, and levels of monoamines and their metabolites following 2 weeks and 2 months of Tat and/or morphine exposure in transgenic mice. Morphine decreased dopamine levels, but significantly elevated norepinephrine, the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), and the serotonin metabolite 5‐hydroxyindoleacetic acid, which typically correlated with increased locomotor behavior. The combination of Tat and morphine altered dopamine, DOPAC, and HVA concentrations differently depending on the neurotransmitter/metabolite and duration of exposure but did not affect the numbers of tyrosine hydroxylase‐positive neurons in the mesencephalon. Tat exposure increased the latency to interact with novel conspecifics, but not other novel objects, suggesting the viral protein inhibits exploratory behavior initiation in a context‐dependent manner. By contrast, and consistent with prior findings that opioid misuse can increase novelty‐seeking behavior, morphine exposure increased the time spent exploring a novel environment. Finally, Tat and morphine interacted to affect locomotor activity in a time‐dependent manner, while grip strength and rotarod performance were unaffected. Together, our results provide novel insight into the unique effects of HIV‐1 Tat and morphine on monoamine neurochemistry that may underlie their divergent effects on motor and exploratory behavior.

Morphine counteracts the antiviral effect of antiretroviral drugs and causes upregulation of p62/SQSTM1 and histone-modifying enzymes in HIV-infected astrocytes

Examining the effects of the HIV‐1 protein Tat and morphine on antiretroviral accumulation and distribution within the brain

A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia.

Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis

HIV-1 coinfection and morphine coexposure severely dysregulate hepatitis C virus-induced hepatic proinflammatory cytokine release and free radical production: increased pathogenesis coincides with uncoordinated host defenses

Escalating morphine dosing in HIV-1 Tat transgenic mice with sustained Tat exposure reveals an allostatic shift in neuroinflammatory regulation accompanied by increased neuroprotective non-endocannabinoid lipid signaling molecules and amino acids

HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity

Opioids Impair Intestinal Epithelial Repair in HIV-Infected Humanized Mice

Chronic Morphine Treatment and Antiretroviral Therapy Exacerbate HIV-Distal Sensory Peripheral Neuropathy and Induce Distinct Microbial Alterations in the HIV Tg26 Mouse Model

Chronic morphine in the context of HIV infection, induce gut microbiome dysbiosis and lead to persistent GALT inflammation. (MUC4P.843)

HIV-1 and methamphetamine co-treatment in primary human astrocytes: TAARgeting ER/UPR dysfunction

Morphine aggravates the apoptosis of simian immunodeficiency virus infected CEM x174 cells in the prolonged culture in vitro.

Chronic morphine and HIV-1 Tat promote differential central nervous system trafficking of CD3+ and Ly6C+ immune cells in a murine Streptococcus pneumoniae infection model

Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization.

HIV‐1 Tat and morphine interactions dynamically shift striatal monoamine levels and exploratory behaviors over time

Tobacco smoke and morphine alter peripheral and CNS inflammation following HIV infection in a humanized mouse model

Opiate effects on in vitro human retroviral infection

Morphine-promoted Survival of CEM×174 Cells in Early Stages of SIV Infection in Vitro: Involvement of the Multiple Molecular Mechanisms

Role of Tumor Necrosis Factor Receptor 1—Reactive Oxygen Species—Caspase 11 Pathway in Neuropathic Pain Mediated by HIV gp120 With Morphine in Rats

Methadone Inhibits Viral Restriction Factors and Facilitates HIV Infection in Macrophages

Deep proteomics and phosphoproteomics reveal novel biological pathways perturbed by morphine, morphine‐3‐glucuronide and morphine‐6‐glucuronide in human astrocytes